摘要
目的:分析盐酸川芎嗪注射液联合吡拉西坦对急性脑梗死(Acute cerebral infarction,ACI)患者血液流变学及血清相关细胞因子水平的影响。方法:回顾性选取2021年5月至2024年4月我院收治的94例ACI患者为研究对象,依据不同治疗方案分为参照组和联合组(n=47),分别采用吡拉西坦以及吡拉西坦联合盐酸川芎嗪注射液治疗14 d。评估治疗14 d后临床疗效,并于治疗前、后采用美国国立卫生研究院卒中量表(National institute of health stroke scale,NIHSS)、脑卒中专门化生活质量表(Stroke-specific quality of life scale,SS-QOL)评估神经功能及生活质量,采用全自动血液流变仪、魏氏法检测血浆黏度、红细胞沉降率(Erythrocyte sedimentation rate,ESR)、全血黏度高切、全血黏度低切水平,采用酶联免疫吸附试验、比色法测定单核细胞趋化蛋白-1(Monocyte chemoattractant protein-1,MCP-1)、白细胞介素-6(Interleukin-6,IL-6)、神经元特异性烯醇化酶(Neuron-specific enolase,NSE)、同型半胱氨酸(Homocysteine,Hcy)、缺氧诱导因子-1α(Hypoxia inducible factor-1α,HIF-1α)、丙二醛(Malondialdehyde,MDA)、超氧化物歧化酶(Superoxide dismutase,SOD)水平,同时记录治疗期间安全性。结果:观察组临床疗效93.62%高于参照组78.72%(P<0.05);与参照组相比,治疗后联合组NIHSS评分更低,SS-QOL评分更高(P<0.05);联合组治疗后全血黏度低切、ESR、全血黏度高切、血浆黏度水平均低于参照组(P<0.05);治疗后联合组IL-6、Hcy、HIF-1α、MDA、MCP-1水平较参照组更低,NSE、SOD水平较参照组更高(P<0.05);两组不良反应发生率相比差异无统计学意义(P>0.05)。结论:盐酸川芎嗪注射液联合吡拉西坦治疗ACI效果显著,能改善血液流变学,抑制炎症发展,缓解神经损伤,促进生活质量恢复,安全性良好。
Objective:To analyze the effects of Ligustrazine hydrochloride injection combined with piracetam on hemorheology and serum levels of related cytokines in patients with acute cerebral infarction(ACI).Methods:A retrospective study was conducted on 94 patients with ACI admitted to our hospital from May 2021 to April 2024.These patients were divided into a reference group and a combination group(n=47)based on different treatment regimens.The reference group was treated with piracetam alone,while the combination group was treated with piracetam in combination with tetramethylpyrazine hydrochloride injection for 14 days.The clinical efficacy was evaluated after 14 days of treatment.The National Institute of Health Stroke Scale(NIHSS)and Stroke-specific quality of life scale(SS-QOL)were used to assess neurological function and quality of life before and after treatment.The levels of plasma viscosity,Erythrocyte sedimentation rate(ESR),whole blood viscosity at high shear,and whole blood viscosity at low shear were measured using a fully automated hemorheology analyzer and the Westergren method.The levels of monocyte chemoattractant protein-1(MCP-1),interleukin-6(IL-6),neuron-specific enolase(NSE),homocysteine(Hcy),hypoxia-inducible factor-1α(HIF-1α),malondialdehyde(MDA),and superoxide dismutase(SOD)were measured using enzyme-linked immunosorbent assay and colorimetric methods.Safety during treatment was also recorded.Results:The clinical efficacy observed was 93.62%,which was higher than the reference group's 78.72%(P<0.05).Compared with the reference group,the NIHSS score was lower and the SS-QOL score was higher in the combined group after treatment(P<0.05).After treatment,the levels of whole blood viscosity low shear,ESR,whole blood viscosity high shear,and plasma viscosity in the combined group were lower than those in the reference group(P<0.05).After treatment,the levels of IL-6,Hcy,HIF-1α,MDA,and MCP-1 in the combined group were lower than those in the reference group,while the levels of NSE and SOD were higher than those in the reference group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Ligustrazine hydrochloride injection and piracetam has significant therapeutic effects on ACI,improving hemorheology,inhibiting inflammation,alleviating nerve damage,and promoting the recovery of quality of life.It has good safety.
作者
魏建军
陶玉梅
Wei Jian-jun;Tao Yu-mei(Department of Neuroendocrinology,Third Affiliated Hospital of Nanyang Medical College,Nanyang 473000,Henan,China)
关键词
急性脑梗死
盐酸川芎嗪注射液
吡拉西坦
血液流变学
因子
Acute cerebral infarction
Ligustrazine hydrochloride injection
Piracetam
Hemorheology
Cytokine
